Bavarian Biotech Report 2011/2012 (7MB) - Bio M

CROS DE GmbHCROKeywords: Dermatology, Pharmacovigiliance, Analysis, Clinical Research,Oncology, Respiratory Diseases, Medical WritingCROS NT is a contract research organisation (CRO) providing outsourcedservices for Clinical Data Management, Statistics, Pharmacovigilance,Medical Writing and Hosting for Pharma-Life Sciences Solutions across allphases of drug development.Established in 1992, CROS NT has completed over 780 studies in a widerange of therapeutic areas like respiratory, oncology, cardiovascular, HIVand Infectious diseases of clinical and observational studies. Our clients andpartners include pharmaceutical, biotechnology, medical device and academicorganizations in Europe and USA. CROS NT Headquarters is in Verona,we have offices in Milan and Augsburg and currently employ 45 people.Contact:Frank FreischlägerKonrad-Adenauer-Allee 1D-86150 AugsburgPhone: +49 (0) 603 250696-16Fax: +49 (0) 821 450807-6E-Mail: frank.freischlaeger@crosnt.comInternet: www.crosnt.comCYTOX, biologische SicherheitsprüfungenCROKeywords: Microscopy, ELISA / EIA, Toxicology, Tissue Engineering / Cell CultureCYTOX provides biological testing service for the medical device and pharmaceuticalindustry by using in vitro toxicological testing procedures accordingto ISO 10993 as well as FDA-compliant processes. Next to classical 2Dcell culture testing systems we use organotypical 3D cell culture systemsespecially in the area of skin irritation testing and REACH applications.Contact:Dr. Dietmar ScheddinGottlieb-Keim-Str. 60D-95448 BayreuthPhone: +49 (0) 921 1511-254Fax: +49 (0) 921 1511-255E-Mail: info@cytox.deInternet: www.cytox.deDAIICHI SANKYO EUROPE GmbHPHARMA & CHEMICAL INDUSTRYKeywords: Antibiotics, Drug DevelopmentDAIICHI SANKYO is a global pharmaceutical company that focuses on researchingand marketing innovative medications. The company was created in2005 through the merger of two traditional Japanese enterprises, Daiichiand Sankyo. With net sales of nearly € 5.9 billion in fiscal year 2008,DAIICHI SANKYO is one of the world‘s 20 leading pharmaceutical companies.The company‘s world headquarters is in Tokyo, and its European base islocated in Munich. DAIICHI SANKYO has affiliates in 12 European countriesand has been one of the strongest Japanese pharmaceutical companieslocated in Europe since it set up European production facilities and marketingoffices in 1990. The company‘s research activities focus on the areas ofcardiovascular diseases, hematology, diabetes, anti-infectives and cancer. Itsaim is to develop medications that are „best“ in their class or to create newclasses of pharmaceutical drugs.For more information, please visit: www.daiichi-sankyo.euContact:Olaf LamberzZielstattstr. 48D-81379 MünchenPhone: +49 (0) 89 7808-0Fax: +49 (0) 89 7808-202E-Mail: service@daiichi-sankyo.euInternet: www.daiichi-sankyo.eu53